Anemia is a Prognostic Factor for Overall Survival Rate in Patients with Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy

References

• GLOBOCAN 2018 [homepage on internet]. Lyon, France: International Agency for Research on Cancer, World Health Organization; [updated September, 2018; cited October 22, 2020]. Available from:http://gco.iarc.fr/today/onlineanalysis-multi-bars?v=2018&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D&population_group_globocan_id=. Accessed 923, 2021.
   Google Scholar
• NCCN Guidelinesfor treatment of cancer by site. Non-small cell lung cancer. 2020 [homepage on internet]. Pennsylvania, US: National Comprehensive Cancer Network; [updated May 21, 2020; cited October 22, 2020]. Available from:https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 923, 2021.
   Google Scholar
• NagataY, HiraokaM, ShibataT, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93(5):989–996. doi:10.1016/j.ijrobp.2015.07.227826581137
   PubMed Web of Science ®Google Scholar
• ChangJY, SenanS, PaulMA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized trial. Lancet Oncol. 2015;16:630–637. doi:10.1016/S1470-2045(15)70168-325981812
   PubMed Web of Science ®Google Scholar
• DubskyP, SeveldaP, JakeszR, et al. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res. 2008;14:2082–2087. doi:10.1158/1078-0432.CCR-07-206818381948
   PubMed Web of Science ®Google Scholar
• KoulisTA, KornagaEN, BanerjeeR, et al. Anemia, leukocytosis and thrombocytosis as prognostic factor in patients with cervical cancer treated with radical chemoradiotherapy: a retrospective cohort study. Clin Transl Radiat Oncol. 2017;4:51–56. doi:10.1016/j.ctro.2017.05.00129594208
   PubMed Web of Science ®Google Scholar
• GuoSS, TangLQ, ChenQY, et al. Is hemoglobin level in patients with nasopharyngeal carcinoma still a significant prognostic factor in the era of intensity-modulated radiotherapy technology?PLoS One. 2015;10:e0136033. doi:10.1371/journal.pone.013603326313452
   PubMed Web of Science ®Google Scholar
• VäyrynenJP, TuomistA, VäyrynenSA, et al. Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival. Sci Rep. 2018;8:1126. doi:10.1038/s41598-018-19572-y29348549
   PubMed Web of Science ®Google Scholar
• HuangXZ, YangYC, ChenY, et al. Preoperative anemia or low hemoglobin predicts poor prognosis in gastric cancer patients: a meta-analysis. Dis Markers. 2019;2019:7606128.30719182
   PubMed Web of Science ®Google Scholar
• LaurieSA, JeyabalanN, NicholasG, MacRaeR, DahrougeS. Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer. J Thorac Oncol. 2006;1:146–151. doi:10.1097/01243894-200602000-0000817409844
   PubMed Web of Science ®Google Scholar
• YovinoS, KwokY, KrasnaM, BangaloreM, SuntharalingamM. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys. 2005;62:1438–1443. doi:10.1016/j.ijrobp.2004.12.03816029805
   PubMed Web of Science ®Google Scholar
• JaziehAR, HussainM, HowingtonJA, et al. Prognostic factors in patients with surgically resected stage I and II non-small cell lung cancer. Ann Thorac Surg. 2000;70:1168–1171. doi:10.1016/S0003-4975(00)01529-011081863
   PubMed Web of Science ®Google Scholar
• ChamogeorgakisT, AnagnostopoulosC, KostopanagiotouG, et al. Does anemia affect outcome after lobectomy or pneumonectomy in early stage lung cancer patients who have not received neo-adjuvant treatment. Thorac Cardiovasc Surg. 2008;56:148–153. doi:10.1055/s-2007-98945518365973
   PubMed Web of Science ®Google Scholar
• HolgerssonG, SandelinM, HoyeE, et al. Swedish lung cancer radiation study group: the prospective value of anemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol. 2012;29:3176–3182. doi:10.1007/s12032-012-0247-322565809
   PubMed Web of Science ®Google Scholar
• LangendijkH, de JongJ, WandersR, LambinP, SlotmanB. The importance pre-treatment haemoglobin level in operable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol. 2003;67:321–325. doi:10.1016/S0167-8140(03)00057-412865181
   PubMed Web of Science ®Google Scholar
• PradierO, LedererK, HilleA, et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with in operable stage III non-small cell lung cancer: a Phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol. 2005;131:261–269. doi:10.1007/s00432-004-0633-015616830
   PubMed Web of Science ®Google Scholar
• TopkanE, SelekU, OzdemirY, et al. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer. Lung Cancer. 2018;121:30–36. doi:10.1016/j.lungcan.2018.04.01629858023
   PubMed Web of Science ®Google Scholar
• ShaverdianN, VeruttipongD, WangJ, KupelianP, SteinbergM, LeeP. Pretreatment anemia portends poor survival and nonlocal disease progression in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. J Thorac Oncol. 2016;11:1319–1325. doi:10.1016/j.jtho.2016.04.03027234604
   PubMed Web of Science ®Google Scholar
• PathakRS, PantarottoJR, CookG, HolmesO, CrossP, MacRaeRM. Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT). Clin Transl Radiat Oncol. 2019;16:28–33. doi:10.1016/j.ctro.2019.01.00330923751
   PubMed Web of Science ®Google Scholar
• HanazawaH, TakahashiS, ShiinokiT, et al. Clinical assessment of coiled fiducial markers as internal surrogates for hepatocellular carcinomas during gated stereotactic body radiotherapy with a real-time tumor-tracking system. Radiother Oncol. 2017;123:43–48. doi:10.1016/j.radonc.2017.02.01028285839
   PubMed Web of Science ®Google Scholar
• Body mass index – BMI [homepage on internet]. Copenhagen, Denmark: World Health Organization Regional Office for Europe; [updated October 13, 2020; cited October 22, 2020]. Available fromhttps://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. Accessed 923, 2021.
   Google Scholar
• HarrisonLB, ChadhaM, HillRJ, HuK, ShashaD. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7:492–508. doi:10.1634/theoncologist.7-6-49212490737
   PubMed Web of Science ®Google Scholar
• SemenzaGL, WangGL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447–5454.1448077
   PubMed Web of Science ®Google Scholar
• ReyS, SemenzaGL. Hypoxia-inducible factor-1-dependent mechanism of vascularization and vascular remodeling. Cardiovasc Res. 2010;86:236–242. doi:10.1093/cvr/cvq04520164116
   PubMed Web of Science ®Google Scholar
• BrownJM, WilsonWR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437–447. doi:10.1038/nrc136715170446
   PubMed Web of Science ®Google Scholar
• JiangJ, TangYL, LiangXH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther. 2011;11:714–723. doi:10.4161/cbt.11.8.1527421389772
   PubMed Web of Science ®Google Scholar
• VarlottoJ, StevensonMA. Anemia, tumor hypoxia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63:25–36. doi:10.1016/j.ijrobp.2005.04.04916111569
   PubMed Web of Science ®Google Scholar
• CoquelleA, ToledoF, SternS, BiethA, DebatisseM. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell. 1998;2:259–265. doi:10.1016/S1097-2765(00)80137-99734364
   PubMed Web of Science ®Google Scholar
• DachsGU, TozerGM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000;36(13):1649–1660. doi:10.1016/S0959-8049(00)00159-310959051
   PubMed Web of Science ®Google Scholar
• MatsuoY, ShibuyaK, NagataY, et al. Prognostic factors in stereotactic body radiotherapy for non-small- cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;79:1104–1111. doi:10.1016/j.ijrobp.2009.12.02220472343
   PubMed Web of Science ®Google Scholar
• TanakaH, HayashiS, HoshiH. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy. Asia Pac J Clin Oncol. 2016;12:e113–e117. doi:10.1111/ajco.1212824176011
   PubMed Web of Science ®Google Scholar